Target Information

Target General Infomation
Target ID
T83001
Former ID
TTDS00016
Target Name
Dopamine reuptake
Synonyms
Dopamine re-uptake
Target Type
Successful
Disease Attention deficit hyperactivity disorder; Severe mood disorders [ICD9: 296, 314.00, 314.01; ICD10: F30-F39, F90]
Anesthesia; Ocular disease [ICD9:338; ICD10: R20.0, H00-H59]
Attention deficit hyperactivity disorder; Depression; Cocaine addiction [ICD9: 303-304, 304.2, 311, 314.00, 314.01; ICD10: F10-F19, F14.2, F32, F90]
Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10: F32, F33, M32]
Neuropathic pain [ICD9: 356.0, 356.8; ICD10: G64, G90.0]
Obesity [ICD9: 278; ICD10: E66]
Severe mood disorders [ICD9: 296; ICD10: F30-F39]
Target Validation
T83001
Drugs and Mode of Action
Drug(s) Cocaine Drug Info Approved Anesthesia; Ocular disease [1], [2], [3]
Phenmetrazine Drug Info Approved Obesity [4]
Bupropion+naltrexone Drug Info Phase 3 Obesity [5]
DOV 21947 Drug Info Phase 2 Severe mood disorders [6]
Amineptine Drug Info Withdrawn from market Major depressive disorder [3]
DOV-216303 Drug Info Discontinued in Phase 2 Severe mood disorders [6]
GSK372475 Drug Info Discontinued in Phase 2 Attention deficit hyperactivity disorder; Severe mood disorders [7]
NS 2359 Drug Info Discontinued in Phase 2 Attention deficit hyperactivity disorder; Depression; Cocaine addiction [6]
Radafaxine Drug Info Discontinued in Phase 2 Major depressive disorder [8]
Radaxafine HCl Drug Info Discontinued in Phase 1 Neuropathic pain [9]
Inhibitor Amineptine Drug Info [10]
Bupropion+naltrexone Drug Info [11]
Cocaine Drug Info [12]
DOV 21947 Drug Info [6]
DOV-216303 Drug Info [6]
GSK372475 Drug Info [6]
Indatraline Drug Info [13]
NS 2359 Drug Info [14]
Phenmetrazine Drug Info [15]
Radafaxine Drug Info [16], [8]
Radaxafine HCl Drug Info [9]
References
REF 1(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2286).
REF 2Drug information of Cocaine, 2008. eduDrugs.
REF 3Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
REF 4Drug information of Phenmetrazine, 2008. eduDrugs.
REF 5A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013 May;21(5):935-43.
REF 6Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2.
REF 7Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder. Drug Des Devel Ther. 2014 Dec 1;8:2321-32.
REF 8Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34.
REF 9Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
REF 10Amineptine in the treatment of amphetamine withdrawal: a placebo-controlled, randomised, double-blind study. J Med Assoc Thai. 1997 Sep;80(9):587-92.
REF 11Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
REF 12Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. Epub 2009 Apr 17.
REF 13Effects of indatraline and buprenorphine on self-administration of speedball combinations of cocaine and heroin by rhesus monkeys. Neuropsychopharmacology. 2001 Jul;25(1):104-17.
REF 14Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
REF 15Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
REF 16Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.